3 recruiting, 1 active not recruiting, 1 terminated. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Active not recruiting 1, Terminated 1 |
Follow Recurrent Oral Cavity Squamous Cell Carcinoma: new trials by email Literature Review of Recurrent Oral Cavity Squamous Cell Carcinoma trials Research Report on Recurrent Oral Cavity Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-10-29 |
| TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Emory University | 40 | 2025-05-08 | 2026-03-04 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer External Beam Radiation Therapy, Intraoperative Radiation Therapy, Pembrolizumab - Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 45 | 2022-05-12 | 2026-07-24 |
| NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery Efineptakin alfa - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Terminated | Hyunseok Kang, MD | 4 | 2021-03-12 | 2025-02-14 |
Squamous Cell Carcinoma of Head and Neck (5) · Carcinoma (3) · Hypopharyngeal Neoplasms (3) · Laryngeal Neoplasms (3) · Mouth Neoplasms (3) · Oropharyngeal Neoplasms (3) · Nasopharyngeal Carcinoma (1) · Recurrence (1) · Salivary Gland Neoplasms (1)
Carcinoma, Squamous Cell (5) · Head and Neck Neoplasms (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Laryngeal Diseases (3) · Mouth Diseases (3) · Otorhinolaryngologic Diseases (3) · Otorhinolaryngologic Neoplasms (3) · Pharyngeal Diseases (3) · Pharyngeal Neoplasms (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Stomatognathic Diseases (3)
Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · pembrolizumab (3) · Radiosurgery (2) · BAY 1895344 (1) · Radiation (1) · Radiotherapy (1) · Surgical Procedures, Operative (1) · efineptakin alfa (1) · gosha-jinki-gan (1)
National Cancer Institute (NCI) (2) · Emory University (1) · Hyunseok Kang, MD (1) · Ohio State University Comprehensive Cancer Center (1)
United States (5)
Yvonne M Mowery (2) · Dong M. Shin, MD, FACP, FAAAS (1) · Dukagjin M Blakaj, MD, PhD (1) · Hyunseok Kang, MD (1)
UM1CA186690 (2), P30CA138292 (1), R01CA262123 (1)